[en] Artemisinin-based combination therapies (ACTs) have been recommended by the World Health Organization (WHO) as first-line treatment of uncomplicated Plasmodium falciparum (P. falciparum) malaria since 2005 in Democratic Republic of Congo (DRC) and a regular surveillance of the ACT efficacy is required to ensure the treatment effectiveness. Mutations in the propeller domain of the pfk13 gene were identified as molecular markers of artemisinin resistance (ART-R). This study investigated the pfk13-propeller gene polymorphism in clinical isolates of P. falciparum collected in the DRC. In 2017, ten geographical sites across DRC were selected for a cross-sectional study that was conducted first in Kinshasa from January to March, then in the nine other sites from September to December. Dried blood samples were collected from patients attending health centers for fever where diagnosis of Malaria was first made by rapid diagnostic test (RDT) available on site (SD Bioline malaria Ag Pf or CareStart Malaria Pf) or by thick blood smear and then confirmed by a P. falciparum real-time PCR assay. A pfk13-propeller segment containing a fragment that codes for amino acids at positions 427-595 was amplified by conventional PCR before sequencing. In total, 1070 patients were enrolled in the study. Real-time PCR performed confirmed the initial diagnosis of P. falciparum infection in 806 samples (75.3%; 95% CI: 72.6%- 77.9%). Of the 717 successfully sequenced P. falciparum isolates, 710 (99.0%; 95% CI: 97.9% - 99.6) were wild-type genotypes and 7 (1.0%; 95% CI: 0.4% - 2.1%) carried non-synonymous (NS) mutations in pfk13-propeller including 2 mutations (A578S and V534A) previously detected and 2 other (M472I and A569T) not yet detected in the DRC. Mutations associated with ART-R in Southeast Asia were not observed in DRC. However, the presence of other mutations in pfk13-propeller gene calls for further investigations to assess their implication in drug resistance.
Disciplines :
Laboratory medicine & medical technology Immunology & infectious disease
Author, co-author :
Yobi, Doudou
Kayiba, Nadine
Mvumbi, Dieudonné
BOREUX, Raphaël ; Centre Hospitalier Universitaire de Liège - CHU > Unilab > Laboratoire biologie moléculaire
Bontems, Sébastien ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Kabututu, Pius
De Mol, Patrick ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Speybroeck, Niko
Mvumbi, Georges
Hayette, Marie-Pierre ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Bact., mycologie, parasitologie, virologie, microbio.
Language :
English
Title :
The lack of K13-propeller mutations associated with artemisinin resistance in Plasmodium falciparum in Democratic Republic of Congo (DRC)
Alternative titles :
[en] Absence de mutation K13 associée à une résistance de l'artémisine chez Plasmodium falciparum en RDC
Publication date :
21 August 2020
Journal title :
PLoS ONE
eISSN :
1932-6203
Publisher :
Public Library of Science, United States - California
Volume :
15
Issue :
8
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
ARES - Académie de Recherche et d'Enseignement Supérieur
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Swarthout TD, Van den Broek IV, Kayembe G, Montgomery J, Pota H and Roper C. Artesunate+amodiaquine and artesunate+sulphadoxine-pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulphadoxine and pyrimethamineresistant haplotypes. Trop Med Int Health 2006; 11(10):1503–11. https://doi.org/10.1111/j.1365-3156.2006.01710.x PMID: 17002724
Vestergaard LS, Ringwald P. Responding to the challenge of antimalarial drug resistance by routine monitoring to update national malaria treatment policies. Am J Trop Med Hyg. 2007; 77:153–9. PMID: 18165488
Cui L, Mharakurwa S, Ndiaye D, Rathod PK, Rosenthal PJ. Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network. Am J Trop Med Hyg. 2015; 93 (3_Suppl):57–68. https://doi.org/10.4269/ajtmh.15-0007 PMID: 26259943
Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014; 371(5):411–23. https://doi.org/10.1056/ NEJMoa1314981 PMID: 25075834
Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014; 505(7481):50–5. https://doi.org/10.1038/nature12876 PMID: 24352242
Ménard D, Khim N, Beghain J, Adegnika AA, ShafiulAlam M, Amodu O, et al. A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. N Engl J Med. 2016; 374(25):2453–2464 https://doi.org/10.1056/NEJMoa1513137 PMID: 27332904
WWARN K13 Genotype-Phenotype Study Group. Association of mutations in the Plasmodium falciparum (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments–a WWARN individual patient data meta-analysis. BMC Medicine 2019; 17: 1 https://doi.org/10.1186/s12916-018-1207-3 PMID: 30651111
World Health Organization/Global Malaria programme. Status report on artemisinin resistance and ACT efficacy (August 2018). https://www.who.int/malaria/publications/atoz/artemisinin-resistanceaugust2018/en/. Accessed April 2019.
Kamau E, Campino S, Amenga-Etego L, Drury E, Ishengoma D, Johnson K, et al. K13 Propeller Polymorphisms in Plasmodium falciparum Parasites from Sub-Saharan Africa: Brief repport. J Infect Dis. 2015; 211: 1352–1355. https://doi.org/10.1093/infdis/jiu608 PMID: 25367300
Ogouyèmi-Hounto A, Damien G, Deme A, Ndam N, Assohou C, Tchonlin D, et al. Lack of artemisinin resistance in Plasmodium falciparum in northwest Benin after 10 years of use of artemisinin-based combination therapy. Parasite 2016; 23:28. https://doi.org/10.1051/parasite/2016028 PMID: 27443837
Taylor S, Parobek C, De Conti D, Kayentao K, Coulibaly S, Greenwood B, et al. Absence of Putative Artemisinin Resistance Mutations Among Plasmodium falciparum in Sub-Saharan Africa: A Molecular Epidemiologic Study. J Infect Dis. 2015; 211(5): 680–8. https://doi.org/10.1093/infdis/jiu467 PMID: 25180240
Tacoli C, Gai P, Bayingana C, Sifft K, Geus D, Ndoli J, et al. Artemisinin Resistance–Associated K13 Polymorphisms of Plasmodium falciparum in Southern Rwanda, 2010–2015. Am J Trop Med Hyg. 2016; 95(5):1090–1093. https://doi.org/10.4269/ajtmh.16-0483 PMID: 27573632
Kakolwa M, Mahende M, Ishengoma D, Mandara C, Ngasala B, Kamugisha E, et al. Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania. Malar J. 2018; 17: 369. https://doi.org/10.1186/s12936-018-2524-x PMID: 30333022
Ikeda M, Kaneko M, Tachibana SI, Balikagala B, Sakurai-Yatsushiro M, Yatsushiro S, et al. Artemisinin-Resistant Plasmodium falciparum with High Survival Rates, Uganda, 2014–2016. Emerg Infect Dis. 2018; 24(4): 718–726. https://doi.org/10.3201/eid2404.170141 PMID: 29553316
Wootton JC, Feng X, Ferdig MT, Cooper RA, Mu J, Baruch DI, et al. Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature 2002; 418 (6895):320–3. https://doi.org/10.1038/ nature00813 PMID: 12124623
Mita T, Venkatesan M, Ohashi J, Culleton R, Takahashi N, Tsukahara T, et al. Limited geographical origin and global spread of sulfadoxine-resistant dhps alleles in Plasmodium falciparum populations. J Infect Dis. 2011; 204(12):1980–8. https://doi.org/10.1093/infdis/jir664 PMID: 22021623
Mvumbi DM, Bobanga TL, Kayembe J-MN, Mvumbi GL, Situakibanza HN-T, Benoit-Vical F, et al. Molecular surveillance of Plasmodium falciparum resistance to artemisinin-based combination therapies in the Democratic Republic of Congo. PLOS ONE. 2017; 12(6):e0179142. https://doi.org/10.1371/journal.pone.0179142 PMID: 28594879
Cnops L, Jacobs J, Esbroeck MV. Validation of a four-primer real-time PCR as a diagnostic tool for single and mixed Plasmodium infections. Clin Microbiol Infect. 2011; 17(7):1101–7. https://doi.org/10.1111/j.1469-0691.2010.03344.x PMID: 20718798
Menard S, Tchoufack JN, Maffo CN, Nsango SE, Iriart X, Abate L, et al. Insight into k13-propeller gene polymorphism and ex vivo DHA-response profiles from Cameroonian isolates. Malar J. 2016; 15(1): 1980–1988.
Mayengue P, Niama R, Batsimba D, Malonga-Massanga A, Louzolo I, Bongolo NC, et al. No polymorphisms in K13-propeller gene associated with artemisinin resistance in Plasmodium falciparum isolated from Brazzaville, Republic of Congo. BMC Infect Dis. 2018; 18:538. https://doi.org/10.1186/s12879-018-3453-6 PMID: 30373565
Kiaco K, Teixeira J, Machado M, Rosário V and Lopes D. Evaluation of artemether-lumefantrine efficacy in the treatment of uncomplicated malaria and its association with pfmdr1, pfatpase6 and K13-propeller polymorphisms in Luanda, Angola. Malar J. 2015; 14:504. https://doi.org/10.1186/s12936-015-1018-3 PMID: 26670642
Mohon A, Alam M, Bayih A, Folefoc A, Shahinas D, Haque R, et al. Mutations in Plasmodium falciparum K13 propeller gene from Bangladesh (2009–2013). Malar J. 2014; 13(1):431.
Laufer M, Plowe C. Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies. Drug Resist Updates 2004, 7:279–88.
President’s Malaria Initiative: Democratic Republic of the Congo—Malaria Operational Plan FY2018. reliefweb.int/report/democratic-republic-congo/presidents-malaria-initiative-democratic-republiccongo-malaria-0. Accessed May 2020.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.